Company: GRCE
Filing Date: 2025-03-10
Form Type: S-3
Source: 0001140361-25-007769
Chunk: 13

Company: Grace Therapeutics, Inc.
Filing Date: 2025-03-10
Form: S-3
Chunk 13
---
 adjusted retroactively, where applicable, to reflect the effect of the change in par value. Effective on October 28, 2024, we changed our corporate name to “Grace Therapeutics, Inc.”.

2

#### TABLE OF CONTENTS
Our principal executive offices are located at 103 Carnegie Center Suite
            300 Princeton, New Jersey, 08540, and our telephone number is (609) 322-1602. Our website address is www.gracetx.com. We do not incorporate the information on, or accessible through, our website into this prospectus, and you should not consider
            any information on, or accessible through, our website as part of this prospectus.

### THE OFFERING
**Shares of Common Stock to be
            offered by the Selling Stockholders

Up to 8,836,584 shares of Common Stock**

#### Use of proceeds
We will not receive any proceeds from the sale of our shares of Common
            Stock offered hereby by the Selling Stockholders, although we will receive the net proceeds of any Warrants exercised for cash.

#### Risk Factors
An investment in our securities involves a high degree of risk. See the
            section entitled “Risk Factors” beginning on page 4 of this prospectus and the similarly titled sections in the documents incorporated by reference into this prospectus for a discussion of factors you should consider before
            deciding to invest in our securities.

#### Nasdaq Capital Market symbol
Our Common Stock is listed on The Nasdaq Capital Market under the symbol
            “GRCE.” We do not intend to apply for listing of the Warrants on any securities exchange or nationally recognized trading system.

<div align='center'>3</div>

#### TABLE OF CONTENTS

### RISK FACTORS
An investment in our securities involves a high degree of risk. Before deciding
          whether to invest in our securities, you should carefully consider the risks discussed under the section entitled “Risk Factors” contained in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024 and other documents that we file
          with the SEC, which are incorporated by reference in this prospectus, together with the information included in this prospectus and documents incorporated by reference herein and therein. If any of these risks actually occurs, our business,
          financial condition, results of operations or cash flow could be harmed. In such case, the trading price of our Common Stock could decline, and our stockholders may lose all or part of their investment in our